Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

Alan Cooper, Sravya Tumuluru, Kyle Kissick, Girish Venkataraman, Joo Y Song, Andrew Lytle, Gerben Duns, Jovian Yu, Nikita Kotlov, Alexander Bagaev, Brendan Paul Hodkinson, Srimathi Srinivasan, Sonali M. Smith, David W. Scott, Christian Steidl, James Godfrey, Justin Kline

Blood (2023) 142 (Supplement 1): 851.

https://doi.org/10.1182/blood-2023-182390

Published: 2023

Journal Articles

Longitudinal Patient-Reported Outcomes (PROs) in a Prospective Registry of CAR T-Cell Therapy Recipients

Ajay Major, Thomas Althaus, Benjamin Brewer, Sarah Schmiege, Justin Kline, Michael R. Bishop, Jamie L Studts, Paul Cook, Peter A. Riedell

Blood (2023) 142 (Supplement 1): 2387.

https://doi.org/10.1182/blood-2023-178398

Published: 2023

Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood (2022) 140 (Supplement 1): 3673–3677.

https://doi.org/10.1182/blood-2022-157583

Published: 2022

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Kirk Cahill, James Godfrey, Chadi Nabhan, Theodore G. Karrison, Jessica Robertson, Justin Kline, Kenneth S. Cohen, Michael R. Bishop, Walter M. Stadler, Reem Karmali, Parameswaran Venugopal, Seo-Hyun Kim, Aaron P. Rapoport, Sonali M. Smith

Blood (2022) 140 (Supplement 1): 6594–6595.

https://doi.org/10.1182/blood-2022-168444

Published: 2022

Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6531–6533.

https://doi.org/10.1182/blood-2022-159823

Published: 2022

Journal Articles

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Blood (2022) 140 (Supplement 1): 2053–2055.

https://doi.org/10.1182/blood-2022-155950

Published: 2022

Journal Articles

A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma

Kirk Cahill, Michael Leukam, Theodore G. Karrison, Jessica Robertson, Justin Kline, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 2420.

https://doi.org/10.1182/blood-2021-152126

Published: 2021

Journal Articles

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

Sravya Tumuluru, James Godfrey, Jovian Yu, Alan Cooper, Xiufen Chen, Gerben Duns, Sonali M. Smith, Christian Steidl, Justin Kline

Blood (2021) 138 (Supplement 1): 449.

https://doi.org/10.1182/blood-2021-153724

Published: 2021

Journal Articles

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Jonathan A. Trujillo, James Godfrey, Yifei Hu, Jun Huang, Sonali M. Smith, Matthew J. Frigault, Zachariah DeFilipp, Daniel Appelbaum, Yonglin Pu, Nicholas Feinberg, Thomas Althaus, Michael R. Bishop, Peter A. Riedell, Justin Kline

Blood (2021) 137 (24): 3454–3459.

https://doi.org/10.1182/blood.2020009148

Published: 2021

Journal Articles

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Ajay Major, MDMBA, Justin Kline, MD, Theodore G. Karrison, PhD, Paul A S Fishkin, MD, Amy S Kimball, MD PhD, Adam M Petrich, MD, Sreenivasa Nattam, MD, Bethany G Sleckman, MD, Kenneth Cohen, MD, Koen van Besien, MD PhD, Aaron P. Rapoport, MD, Sonali M. Smith, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-134750

Published: 2020

Journal Articles

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

Jovian Yu, MD, Xiufen Chen, PhD, James Godfrey, MD, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Mengjie Chen, PhD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-137171

Published: 2020

Journal Articles

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

James Godfrey, MD, Wenjun Kang, MS, Lei Huang, PhD, Silvia Coma, PhD, Roy Maute, PhD, Mark P. Chao, MD PhD, Jonathan A Pachter, PhD, Sonali Smith, MD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-143304

Published: 2020

Journal Articles

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Hongtao Liu, MD PhD, Bulent Aydogan, MD, Yasmin Hasan, MD, Amy Wang, MD MPH, Kamil Yenice, MD, Julien Partouche, MD, Wendy Stock, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, James LaBelle, MD PhD, Justin Kline, MD, Peter A. Riedell, MD, Andrew S. Artz, MD, Michael R. Bishop, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138554

Published: 2020

Journal Articles

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Justin Kline, James Godfrey, Stephen M. Ansell

Blood (2020) 135 (8): 523–533.

https://doi.org/10.1182/blood.2019000847

Published: 2020

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Nicole Sunseri, MD PhD, Xiufen Chen, PhD, Noemie Wald, PhD, Julie Preillon, PhD, Sonali M. Smith, MD, Gregory Driessens, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 391.

https://doi.org/10.1182/blood-2019-131493

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

https://doi.org/10.1182/blood-2019-126211

Published: 2019

NARROW

A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

Longitudinal Patient-Reported Outcomes (PROs) in a Prospective Registry of CAR T-Cell Therapy Recipients

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only